Autolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel

MT Newswires Live

昨天

Autolus Therapeutics (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus erythematosus and lupus nephritis.

The designation is intended to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, to treat serious or life-threatening diseases.

The company said the designation was based on data from the phase 1b CARLYSLE trial in patients with systemic lupus erythematosus.

Shares of the British biotech firm were up 3.8% pre-bell.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2666580908"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666580908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666580908?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-09 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666580908","market":"us","top_or_hot":-1,"title":"Autolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel","media":"MT Newswires Live","content":"<html><body><p> Autolus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus erythematosus and lupus nephritis.</p><p>The designation is intended to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, to treat serious or life-threatening diseases.</p><p>The company said the designation was based on data from the phase 1b CARLYSLE trial in patients with systemic lupus erythematosus.</p><p>Shares of the British biotech firm were up 3.8% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Autolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAutolus Receives FDA Regenerative Medicine Advanced Therapy Designation for Obecabtagene Autoleucel\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-09 19:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Autolus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus erythematosus and lupus nephritis.</p><p>The designation is intended to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, to treat serious or life-threatening diseases.</p><p>The company said the designation was based on data from the phase 1b CARLYSLE trial in patients with systemic lupus erythematosus.</p><p>Shares of the British biotech firm were up 3.8% pre-bell.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2931357623.SGD","symbol_name":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666580908","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666580908","pubTimestamp":1788954145,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Autolus Therapeutics (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2931357623.SGD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (SGDHDG) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","AUTL":"Autolus Therapeutics PLC","LABU":"三倍做多标普生物-Direxion","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4588":"碎股","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","LU2089985449.USD":"MANULIFE GF GLOBAL SEMICONDUCTOR OPPORTUNITIES \"AA\" (USD) ACC","BK4585":"ETF&股票定投概念","AEIS":"先进能源工业公司","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC","BK4139":"生物科技","BK4157":"电子设备和仪器","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC"},"translate_title":"Autolus Obecabtagene Autoleucel 获得 FDA 再生医学高级疗法认证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUTL":1,"LABU":1.5,"AEIS":1.5},"content_text":"Autolus Therapeutics (AUTL) said Wednesday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation for obecabtagene autoleucel to treat systemic lupus erythematosus and lupus nephritis.The designation is intended to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, to treat serious or life-threatening diseases.The company said the designation was based on data from the phase 1b CARLYSLE trial in patients with systemic lupus erythematosus.Shares of the British biotech firm were up 3.8% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}